120 related articles for article (PubMed ID: 18714178)
1. Low prevalence of CDKN2A/ARF mutations among early-onset cancers of breast, pancreas and malignant melanoma in Poland.
Debniak T; van de Wetering T; Scott R; Nagay L; Cybulski C; Górski B; Jakubowska A; Gronwald J; Masojć B; Huzarski T; Byrski T; Nej-Wołosiak K; Kładny J; Maleszka R; Lubinski J
Eur J Cancer Prev; 2008 Oct; 17(5):389-91. PubMed ID: 18714178
[TBL] [Abstract][Full Text] [Related]
2. Germline mutations in CDKN2A are infrequent in female patients with melanoma and breast cancer.
Nagore E; Montoro A; García-Casado Z; Botella-Estrada R; Insa A; Lluch A; López-Guerrero JA; Guillén C
Melanoma Res; 2009 Aug; 19(4):211-4. PubMed ID: 19571771
[TBL] [Abstract][Full Text] [Related]
3. CDKN2A-positive breast cancers in young women from Poland.
Debniak T; Cybulski C; Górski B; Huzarski T; Byrski T; Gronwald J; Jakubowska A; Kowalska E; Oszurek O; Narod SA; Lubiński J
Breast Cancer Res Treat; 2007 Jul; 103(3):355-9. PubMed ID: 17061045
[TBL] [Abstract][Full Text] [Related]
4. A common variant of CDKN2A (p16) predisposes to breast cancer.
Debniak T; Górski B; Huzarski T; Byrski T; Cybulski C; Mackiewicz A; Gozdecka-Grodecka S; Gronwald J; Kowalska E; Haus O; Grzybowska E; Stawicka M; Swiec M; Urbański K; Niepsuj S; Waśko B; Góźdź S; Wandzel P; Szczylik C; Surdyka D; Rozmiarek A; Zambrano O; Posmyk M; Narod SA; Lubinski J
J Med Genet; 2005 Oct; 42(10):763-5. PubMed ID: 15879498
[TBL] [Abstract][Full Text] [Related]
5. CDKN2A common variants and their association with melanoma risk: a population-based study.
Debniak T; Scott RJ; Huzarski T; Byrski T; Rozmiarek A; Debniak B; Załuga E; Maleszka R; Kładny J; Górski B; Cybulski C; Gronwald J; Kurzawski G; Lubinski J
Cancer Res; 2005 Feb; 65(3):835-9. PubMed ID: 15705881
[TBL] [Abstract][Full Text] [Related]
6. Multiple primary melanoma revisited.
Blackwood MA; Holmes R; Synnestvedt M; Young M; George C; Yang H; Elder DE; Schuchter LM; Guerry D; Ganguly A
Cancer; 2002 Apr; 94(8):2248-55. PubMed ID: 12001124
[TBL] [Abstract][Full Text] [Related]
7. Germline mutation and large deletion analysis of the CDKN2A and ARF genes in families with multiple melanoma or an aggregation of malignant melanoma and breast cancer.
Debniak T; Górski B; Scott RJ; Cybulski C; Medrek K; Zowocka E; Kurzawski G; Debniak B; Kadny J; Bielecka-Grzela S; Maleszka R; Lubiński J
Int J Cancer; 2004 Jul; 110(4):558-62. PubMed ID: 15122588
[TBL] [Abstract][Full Text] [Related]
8. Lifetime risk of melanoma in CDKN2A mutation carriers in a population-based sample.
Begg CB; Orlow I; Hummer AJ; Armstrong BK; Kricker A; Marrett LD; Millikan RC; Gruber SB; Anton-Culver H; Zanetti R; Gallagher RP; Dwyer T; Rebbeck TR; Mitra N; Busam K; From L; Berwick M;
J Natl Cancer Inst; 2005 Oct; 97(20):1507-15. PubMed ID: 16234564
[TBL] [Abstract][Full Text] [Related]
9. Familial melanoma, pancreatic cancer and germline CDKN2A mutations.
Goldstein AM
Hum Mutat; 2004 Jun; 23(6):630. PubMed ID: 15146471
[TBL] [Abstract][Full Text] [Related]
10. Analysis of mutations in the p16/CDKN2A gene in sporadic and familial melanoma in the Polish population.
Lamperska K; Karezewska A; Kwiatkowska E; Mackiewicz A
Acta Biochim Pol; 2002; 49(2):369-76. PubMed ID: 12362978
[TBL] [Abstract][Full Text] [Related]
11. Heterogeneity of risk for melanoma and pancreatic and digestive malignancies: a melanoma case-control study.
Rutter JL; Bromley CM; Goldstein AM; Elder DE; Holly EA; Guerry D; Hartge P; Struewing JP; Hogg D; Halpern A; Sagebiel RW; Tucker MA
Cancer; 2004 Dec; 101(12):2809-16. PubMed ID: 15529312
[TBL] [Abstract][Full Text] [Related]
12. Role of the CDKN2A locus in patients with multiple primary melanomas.
Puig S; Malvehy J; Badenas C; Ruiz A; Jimenez D; Cuellar F; Azon A; Gonzàlez U; Castel T; Campoy A; Herrero J; Martí R; Brunet-Vidal J; Milà M
J Clin Oncol; 2005 May; 23(13):3043-51. PubMed ID: 15860862
[TBL] [Abstract][Full Text] [Related]
13. The CDKN2A p.A148T variant is associated with cutaneous melanoma in Southern Brazil.
Bakos RM; Besch R; Zoratto GG; Godinho JM; Mazzotti NG; Ruzicka T; Bakos L; Santos SE; Ashton-Prolla P; Berking C; Giugliani R
Exp Dermatol; 2011 Nov; 20(11):890-3. PubMed ID: 21895773
[TBL] [Abstract][Full Text] [Related]
14. High prevalence of germline CDKN2A mutations in Slovenian cutaneous malignant melanoma families.
Hocevar M; Avbelj M; Perić B; Zgajnar J; Besić N; Battelino T
Croat Med J; 2006 Dec; 47(6):851-4. PubMed ID: 17167857
[TBL] [Abstract][Full Text] [Related]
15. Confirmed cancer trends in families of patients with multiple cancers including cutaneous melanoma.
Nielsen K; Masback A; Bladstrom A; Lundgren L; Jonsson N; Borg A; Ingvar C; Olsson H
Br J Dermatol; 2008 Feb; 158(2):429-31. PubMed ID: 18047508
[No Abstract] [Full Text] [Related]
16. Prevalence of the E318K and V320I MITF germline mutations in Polish cancer patients and multiorgan cancer risk-a population-based study.
Gromowski T; Masojć B; Scott RJ; Cybulski C; Górski B; Kluźniak W; Paszkowska-Szczur K; Rozmiarek A; Dębniak B; Maleszka R; Kładny J; Lubiński J; Dębniak T
Cancer Genet; 2014 Apr; 207(4):128-32. PubMed ID: 24767713
[TBL] [Abstract][Full Text] [Related]
17. A novel type of deletion in the CDKN2A gene identified in a melanoma-prone family.
Knappskog S; Geisler J; Arnesen T; Lillehaug JR; Lønning PE
Genes Chromosomes Cancer; 2006 Dec; 45(12):1155-63. PubMed ID: 17001621
[TBL] [Abstract][Full Text] [Related]
18. Genetic testing in familial melanoma: uptake and implications.
de Snoo FA; Riedijk SR; van Mil AM; Bergman W; ter Huurne JA; Timman R; Bertina W; Gruis NA; Vasen HF; van Haeringen A; Breuning MH; Tibben A
Psychooncology; 2008 Aug; 17(8):790-6. PubMed ID: 18613292
[TBL] [Abstract][Full Text] [Related]
19. The CDKN2a common variants: 148 Ala/Thr and 500 C/G in 3' UTR, and their association with clinical course of melanoma.
Lamperska KM; Przybyła A; Kycler W; Mackiewicz A
Acta Biochim Pol; 2007; 54(1):119-24. PubMed ID: 17351674
[TBL] [Abstract][Full Text] [Related]
20. Increased prevalence of lung, breast, and pancreatic cancers in addition to melanoma risk in families bearing the cyclin-dependent kinase inhibitor 2A mutation: implications for genetic counseling.
Potrony M; Puig-Butillé JA; Aguilera P; Badenas C; Carrera C; Malvehy J; Puig S
J Am Acad Dermatol; 2014 Nov; 71(5):888-95. PubMed ID: 25064638
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
